-
Progress Report: Aligos Therapeutics’ SUPREME Trial in Hepatitis B
NASDAQ: $ALGS Aligos Therapeutics recently issued an update concerning the progress of its Phase 2b SUPREME study, a significant development in the ongoing effort to find effective treatments for chronic Hepatitis B virus (HBV) infection. For those following pharmaceutical advancements in virology, this announcement provides valuable insight into the trajectory of their lead candidate. The…
-
Exciting Progress: Corvus Pharmaceuticals Poised to Share Promising Data on Soquelitinib for Atopic Dermatitis
NASDAQ: $CRVS Pharmaceutical research is a journey of meticulous steps, and today, the spotlight shines brightly on Corvus Pharmaceuticals as they prepare to share significant updates from their ongoing clinical investigations. Specifically, the market and the patient community are eagerly anticipating the forthcoming announcement regarding the results from Cohort 4 of the placebo-controlled Phase 1…